ArticleClinical and translational medicine2014
Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development.
Article in Clinical and translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Proteomic Biomarkers Associated with Low Bone Mineral Density: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies.International journal of environmental research and public health · 2020Pooled it
- Examining the gene network and prognostic biomarkers in the onset of colorectal cancer in stool samples using machine learning.Discover oncology · 2026Article
- Comprehensive molecular characterization and comparison of venom proteins and transcripts in three Gloydius species from South Korea.Scientific reports · 2026Article
- Novel CSF biomarkers for facilitating diagnosis of CNS-HLH from other neuroinflammatory disorders.Blood advances · 2026Article
- Proteomic signals are not equal clinical phenotypes: redefining evidence standards in arbovirus-SARS-CoV-2 cross-reactivity.Frontiers in immunology · 2026Review
- PTMFusionNet: A Deep Learning Approach for Predicting Disease Related Post-translational Modification and Classifying Disease Subtypes.Molecular & cellular proteomics : MCP · 2025Article
- Multi-omic signatures of host response associated with presence, type, and outcome of enterococcal bacteremia.mSystems · 2025Article
- Robust Glycoproteomics Platform Reveals a Tetra-Antennary Site-Specific Glycan Capping with Sialyl-Lewis Antigen for Early Detection of Gastric Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Bioinformatics tools and data resources for assay development of fluid protein biomarkers.Biomarker research · 2022Review
- New Paradigms of Old Psychedelics in Schizophrenia.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Article
- Tutorial: best practices and considerations for mass-spectrometry-based protein biomarker discovery and validation.Nature protocols · 2021Review
- The geometry of clinical labs and wellness states from deeply phenotyped humans.Nature communications · 2021Article
- Prospection of plasma proteins as biomarkers for diabetes mellitus monitoring.Journal of diabetes and metabolic disorders · 2021Article
- Proteomic Characterization of Canine Gastric Fluid by Liquid Chromatography-Mass Spectrometry for Development of Protein Biomarkers in Regurgitation, Vomiting, and Cough.Frontiers in veterinary science · 2021Article
- Article
- Article
- Differential Urinary Proteome Analysis for Predicting Prognosis in Type 2 Diabetes Patients with and without Renal Dysfunction.International journal of molecular sciences · 2020Article
- Serum IGFBP-1 as a potential biomarker for diagnosis of early-stage upper gastrointestinal tumour.EBioMedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biomarker research is continuously expanding in the field of clinical proteomics. A combination of different proteomic-based methodologies can be applied depending on the specific clinical context of use. Moreover, current advancements in proteomic analytical platforms are leading to an expansion of biomarker candidates that can be identified. Specifically, mass spectrometric techniques could provide highly valuable tools for biomarker research. Ideally, these advances could provide with biomarkers that are clinically applicable for disease diagnosis and/ or prognosis. Unfortunately, in general the biomarker candidates fail to be implemented in clinical decision making. To improve on this current situation, a well-defined study design has to be established driven by a clear clinical need, while several checkpoints between the different phases of discovery, verification and validation have to be passed in order to increase the probability of establishing valid biomarkers. In this review, we summarize the technical proteomic platforms that are available along the different stages in the biomarker discovery pipeline, exemplified by clinical applications in the field of bladder cancer biomarker research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.